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Abstract
Objective: To perform a critical evaluation of the more recent H1 antihistamines and the various terms used to
describe them, based on a review of evidence on their role in the treatment of allergic disorders.
Sources: Original articles, reviews and consensus documents published from 1998 to 2006 and indexed in the
MEDLINE and PubMed databases. Keyword: antihistamines.
Summary of the findings: Second-generation antihistamines differ from first-generation ones because of their
elevated specificity and affinity for peripheral H1 receptors and because of their lower penetration of the central nervous
system (CNS), having fewer sedative effects as a result. Whilst second-generation antihistamines are in general better
tolerated than their predecessors, some adverse effects, principally cardiotoxicity, have been observed with some of
them. Over the last 20 years, new compounds with different pharmacokinetic properties have been synthesized. The
majority of these exhibit anti-inflammatory properties that are independent of their action on the H1 receptor. More
recent improvements, generally in the form of active metabolites, led to the use of the term third-generation
antihistamines. This term emerged spontaneously, with no clear definition of its meaning or clinical implications, creating
great confusion among healthcare professionals.
Conclusions: On the basis of the evidence on H1 antihistamines, none of them deserve the title third-generation
antihistamine. As the Consensus Group on New Generation Antihistamines concluded, to merit this definition, a new
class of antihistamines would have to demonstrate distinct clinical advantages over existing compounds and fulfill at least
three prerequisites: they should be free from cardiotoxicity, drug interactions and effects on the CNS.
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Introduction
Several different mediators are involved in the
pathophysiology of allergic diseases. Despite this, histamine
remains the principal one, and plays a fundamental role in
the genesis of these diseases, particularly rhinitis and
urticaria. Produced and stored within the cytoplasmic
granules of mast cells and basophils, histamine is already
liberated in large quantities during the immediate phase of
allergic reactions.1
To date four subtypes of histamine receptors have
been described (H1, H2, H3 and H4). They all belong to the
superfamily of G protein-coupled receptors2 and differ in
terms of location, secondary messengers and histamine-
binding properties.3 Histamine exerts its effects in allergic
diseases primarily interacting with H1 receptors present in
a variety of organs.
In the nose histamine stimulates the sensory nerve
endings (itching and sneezing), increases vascular
permeability (edema and obstruction) and glandular
secretions (rhinorrhea). In the skin it provokes vasodilation
and increase in vascular permeability (erythema and
edema) and stimulates sensory nerve endings (itching).
In the lungs it primarily acts on the bronchial smooth
muscle (bronchoconstriction).1,4
Chronically, histamine has effects on inflammatory
cells and causes cellular activation (mast cells, basophils
and eosinophils) and release of proinflammatory
mediators (for example, leukotrienes and cytokines);
and increases in the expression of class II human
histocompatibility molecules (HLA) and vascular
endothelial adhesion molecules.5,6
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Antihistamines
Antihistamines are described according to the
histamine receptor with which they interact. Thus, those
that have a predilection for H1 receptors, H2, H3 and H4
are called, H1 antihistamines, H2 antihistamines, H3
antihistamines and H4 antihistamines, respectively. It is
H1 antihistamines that are most often used for treating
allergic disorders.
Mechanisms of action of H1 antihistamines:
treatment rationale
H1 antihistamines are among the most prescribed
medications in the world and, although they have similar
efficacy for the treatment of patients with allergic
rhinoconjunctivitis, urticaria and other allergic diseases,
they differ significantly in terms of their chemical structure,
clinical pharmacology and toxicity potential.7 Depending
on their action on the central nervous system (CNS), they
are classified as classic, or first-generation, and non-
classic, or second-generation.
In general, first-generation H1 antihistamines (for
example, dexchlorpheniramine and hydroxyzine) are
rapidly absorbed and metabolized, which means they
must be administered three or four times a day. Since they
have reduced molecular structures and are highly lipophilic,
they cross the blood-brain barrier (BBB), bind with ease to
the cerebral H1 receptors and thereby create their principal
side-effect: sedation.5
Over the last 20 years, second-generation H1
antihistamines were synthesized compounds with high
potency, long-lasting effect and minimal adverse effects.
They are unlikely to cross the BBB and rarely cause
sedation.5 In Brazil the following are available for oral use:
cetirizine, ebastine, epinastine, fexofenadine, loratadine,
desloratadine, levocetirizine and rupatadine. As a result of
their high-affinity for the H1 receptors, they have a
prolonged half-life, which means they need only be taken
once or twice a day.
Effects on the H1 receptor
For years it was believed that H1 antihistamines
acted as competitive histamine antagonists, blocking
the site where histamine binds with receptors. Recently
it became clear that there are two H1 receptor isoforms,
an active and an inactive form, which are in equilibrium
on cell surfaces.2 It was realized that the receptors have
agonist-independent signal transduction, in other
words, even in the absence of histamine they are
constitutively in the on position - activate. Therefore,
it is believed that H1 antihistamines inhibit this
constitutive signal and stabilize the receptors inactive
configuration, acting, therefore, as inverse agonists and
not as antagonists.2
Traditionally, the efficacy of H1 antihistamines for
treatment of allergic diseases has been primarily attributed
to their capacity to downregulate the activity of histamine
on H1 receptors located on endothelial cells, airway
smooth muscle and sensory nerve endings. Thus they are
capable of a) reducing vascular permeability, vasodilation
and glandular secretion, improving rhinorrhea, erythema
and cutaneous edema; b) promote bronchodilation; and c)
reduce sneezing and itching of nasal mucosa and skin.1
Antiallergic/anti-inflammatory effects
Originally, studies of the relative potencies of H1
antihistamines were based on the capacity of different
compounds to competitively inhibit the H1 receptor binding
of histamine, i.e. on their blocking effect on the receptor.8
Nevertheless, it has already been known for some time
that, in addition to acting on H1 receptors, many H1
antihistamines, at appropriate doses, are capable of
inhibiting not only the release of histamine by mast
cells,9,10 but also mast cell activation itself.11 Some of
them can even regulate the expression and/or release of
cytokines, chemokines, adhesion molecules and
inflammatory mediators.5,8
Therefore, the antiallergic properties of H1
antihistamines are generally a reflection of their capacity
to affect mast cell and basophil activity, inhibiting the
release of preformed mediators such as histamine,
tryptase, leukotrienes and others.8 Several second-
generation H1 antihistamines have demonstrated
antiallergic properties, irrespective of their interaction
with the H1 receptor.5,8
Chronic allergic inflammation resulting from the
late-phase reaction, exhibits components that are similar
to other forms of inflammation, including chemotaxis of
inflammatory cel ls fol lowed by activation and
proliferation, with subsequent production and release of
many chemical mediators. Among cells involved in
allergic inflammation are: antigen-presenting cells (for
example, macrophages), mast cells, basophils, T
lymphocytes, epithelial/endothelial cells and eosinophils
 major effectors of chronic inflammation. Cytokines,
chemokines, inflammatory mediators and adhesion
molecules also contribute to this process which ultimately
leads to dysfunction of the affected organ.8
Many second-generation H1 antihistamines (particularly
cetirizine) are capable of inhibiting the influx of eosinophils
to the site of allergen challenge in sensitized individuals.5,8
Studies have demonstrated that some of them can also
alter adhesion molecules expression on epithelium and
eosinophils, and reduce in vitro survival of eosinophils.
Finally, some second-generation H1 antihistamines are
capable, in vitro and in vivo, of altering the production of
inflammatory cytokines (for example, TNF-α, IL-1ß and
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IL-6) and the Th1/Th2 balance regulation cytokines (for
example, IL-4 and IL-13).5,8
Therefore, it is well established that, in addition to their
effects on H1 receptors, many second-generation H1
antihistamines also manifest antiallergic and anti-
inflammatory properties which differ depending upon
their molecules and the experiments used for their
evaluation.5
Clinical and pharmacological effects
The scientific basis for the use of antihistamines with
maximum efficacy in all types of patients (young, elderly,
patients with hepatic or renal dysfunction or on other
medication) is documented in pharmacokinetic and
pharmacodynamic studies.7 Clinical efficacy in humans
does not only depend on the potency and specificity of the
H1 antihistamine, but also on its concentration at the
receptor site.1
Second-generation H1 antihistamines have high affinity
and selectivity for the H1 receptor. After oral administration
at usual dosages, they rapidly achieve peak concentration
in tissues.1,7 The majority of them begin to act 1 to 2 hours
after administration, with effects manifest for 24 hours,
and so can be taken once a day.7
Their activity does not diminish with regular, daily use
for prolonged periods. These compounds maintain the
capacity both to suppress the wheal and flare induced by
histamine and to control the symptoms of persistent
allergic rhinitis and chronic urticaria, for weeks and
months.1
In patients with allergic rhinitis (AR), H1 antihistamines
improve itching, sneezing and watery rhinorrhea. However,
they are not so useful for controlling nasal obstruction.
When administered orally, they exert their effect, not only
on nasal symptoms, but also on ocular symptoms, which
are frequently associated with AR.5
Evidence shows that continual use is of greater
advantage and more effective than an on-demand
regimen.5 In children, treatment for prolonged periods
can even improve lower airway symptoms12 and have a
prophylactic effect on asthma onset in monosensitized
infants (to dust mites or grass pollen).13
Since H1 antihistamines are often prescribed for
prolonged periods, the possibility that they may interact
with other drugs should always be taken into
consideration. All second-generation H1 antihistamines,
with the exception of cetirizine, levocetirizine and
fexofenadine, are metabolized via the cytochrome
system. The P4503A (CYP3A) cytochrome, is known to
be involved in the metabolism of many drugs used on
humans. Drug interactions causing enzymatic inhibition
or induction are common after the coadministration of
two or more CYP3A substrates.5
Therefore, the administration of H1 antihistamines
that are metabolized via the P450 cytochrome, in association
with other drugs that employ the same route (for example,
ketoconazole and erythromycin), increases the risk of
adverse reactions.5
Side effects of H1 antihistamines
Central nervous system
H1 receptors can be found widely distributed throughout
the CNS and, although their physiological role in these
locations is not yet fully understood, H1 antihistamines
can cause several effects within the CNS, namely: a)
sedation, varying from mild somnolence to deep sleep; b)
depression, identified by symptoms such as coordination
disturbance, dizziness, lassitude and lack of concentration;
and c) agitation.5
An important determinant of the occurrence of CNS
side effects is the greater or lesser capacity a compound
has to cross the BBB. Crossing the BBB basically depends
on the existence of an active transport mechanism for the
H1 antihistamine and on certain of its chemical properties,
such as its lipophilicity and molecular weight. Furthermore,
there is an important correlation between the sedation
caused by an H1 antihistamine and its degree of affinity for
the H1 receptors in the CNS.5
First-generation H1 antihistamines are highly
liposoluble, they have low molecular weight and a high
degree of affinity for cerebral H1 receptors, which means
that sedation occurs with frequency, even at therapeutic
doses. Second-generation H1 antihistamines, in contrast,
have greater molecular weight, low liposolubility and low
affinity for cerebral H1 receptors. Therefore, the majority
of compounds in this generation, at therapeutic doses, are
apparently devoid of significant side effects on the CNS.5,14
Cardiac effects
One important precaution that must be taken with H1
antihistamines relates to their potential for cardiotoxicity.
These cardiotoxic effects are apparently dose-dependent,
which is an extremely important fact with relation to drugs
metabolized by the P450 cytochrome, since concurrent
administration of compounds that compete for the same
enzyme may reduce the rate at which the H1 antihistamine
is metabolized, increasing its concentration in plasma.5
During the last 20 years adverse cardiac effects were
reported (torsades de pointes, arrhythmia, prolongation
of the QTc interval) with two second-generation H1
antihistamines: astemizole and terfenadine.5,15 In these
cases the compounds were invariably being administrated
at doses above the recommended levels, or in association
with drugs that use the same hepatic metabolism route
(ketoconazole, erythromycin). It is important to point out
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that these effects are not drug class-specific, but are
limited to terfenadine and astemizole, which were
withdrawn from the market in many countries,5 including
Brazil.
Cetirizine,16 fexofenadine17,18 and levocetirizine,19,20
are minimally metabolized and so are safer.
Others
The majority of first-generation H1 antihistamines, if
not all of them, exhibit pharmacological effects that are
not related to their binding with H1 receptors. The principal
of these is the anticholinergic effect, resulting from their
capacity to bind to muscarinic receptors, causing dry
mouth, tachycardia and urinary retention.5 These effects
have not been reported with second-generation H1
antihistamines.5
More recent antihistamines
Desloratadine
Desloratadine (DL) is an active metabolite of loratadine
which has a high affinity for binding with H1 receptors.
Despite this, it also interacts with the five subtypes of
muscarinic receptors, which suggests that it has less
selectivity for the H1 receptor when compared with other
H1 antihistamines of the same generation.21
After oral administration, DL is rapidly absorbed and is
metabolized on its first passage through the liver via the
P450 cytochrome. Although this would imply a potential
for interaction with other drugs that are metabolized via
the same route (for example, erythromycin and
ketoconazole), there is no direct evidence that this does
actually take place.22,23 As a result of its pharmacokinetic
and pharmacodynamic characteristics, its effects are long-
lasting and it can be taken just once a day.
Studies of the action of DL in skin have demonstrated
that it has a potent suppressive effect on histamine-
induced wheal and flare.24,25 In patients with AR subjected
to nasal challenge, DL promoted significant improvement
in nasal flow and symptom score, when compared with a
placebo.26-28
Antiallergic and anti-inflammatory effects have been
described in vitro29 and in vivo.30 Double-blind, placebo-
controlled trials, with adults and children over 12 years
old, indicate that DL (5 mg/day) is effective for the
treatment of seasonal AR,26,31 perennial AR32 and
intermittent AR,33 improving all nasal symptoms including
obstruction,31,32 associated non-nasal symptoms32 and
quality of life.31 In multicenter, randomized, double-
blind, placebo-controlled trials undertaken with adults
with chronic idiopathic urticaria, DL (5 mg/day) was able
to improve, to a significant extent, patients symptoms
and their quality of life.34,35
Desloratadine was shown to be safe and effective for
the treatment of AR and chronic idiopathic urticaria in
children aged 2 to 5 years and 6 to 11 years at dosages
of 1.25 mg and 2.5 mg, respectively.36 This is a well-
tolerated compound, with a minimal incidence of adverse
effects that is comparable with placebo.31-33,36
Desloratadine does not induce clinically relevant
alterations to the QTc interval,34,36 even in individuals
given drugs that employ the same hepatic metabolism
route.22,23 Despite its potential for interaction with
muscarinic receptors, no significant anticholinergic effects
have been reported.37 Compared with placebo, DL does
not produce significant sedation, nor any marked effect on
cognitive or psychomotor functions in healthy volunteers,38
or patients with seasonal AR.39
Fexofenadine
Fexofenadine (FEX), the pharmacologically active
metabolite of terfenadine, exhibits high affinity and
selectivity for peripheral H1 receptors. It does not cross
the BBB, is minimally metabolized and its pharmacokinetic
properties allow it to be taken in a single daily dose.5,40,41
In models constructed to evaluate its action in skin,
FEX revealed a potent suppressive effect over histamine-
induced wheal and flare.9,10,42 In patients with AR subjected
to nasal challenge it promoted significant improvement in
nasal flow and symptom score, when compared with a
placebo.28
Antiallergic and anti-inflammatory effects have been
described in vitro.43 Double-blind, placebo-controlled
clinical trials indicate that, in adults, FEX, at doses of 120
to 180 mg/day, is effective for the treatment of seasonal
and perennial AR, improving all nasal symptoms, including
obstruction44,45 and also associated ocular symptoms.44
In children aged 6 to 11 years, the same efficacy was
demonstrated using FEX at 60 mg/day for seasonal and
perennial AR.46,47 Compared with placebo, FEX (120 or
180 mg/day) significantly improved quality of life and
reduced the impairment of performance at work and
during daily activities that is frequently associated with the
symptoms of AR.48
Multicenter, randomized, double-blind, placebo-
controlled studies have demonstrated that FEX at 120-180
mg/day is capable of significantly improving the
symptoms49,50 and quality of life of patients with chronic
idiopathic urticaria.49 Evidence indicates that FEX is safe
and well-tolerated,44-47,50 even at doses up to 11 times
the therapeutic dose.40 It is devoid of clinically significant
anticholinergic effects.51
No other H1 antihistamine has been studied as much
as FEX to investigate potential cardiotoxic effects. Its
cardiovascular safety has been convincingly demonstrated
at many different dosages, administered at differing
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intervals, in isolation or in association with other potentially
cardiotoxic drugs.17,18
With relation to its effect on the CNS, when compared
with placebo FEX did not cause any significant adverse
effect whatsoever on the cognitive or psychomotor functions
of healthy volunteers.14,52 Similarly, the frequency of
sedation was comparable with that observed with placebo.41
Levocetirizine
Levocetirizine (LEV) is the active R-enantiomer of
cetirizine. It has high selectivity and affinity for H1
receptors  around twice as great as the affinity of
cetirizine. Its is rapidly and extensively absorbed, and
minimally metabolized. Its pharmacological properties
guarantee prolonged effect and it can be given once a
day.19,20
Levocetirizine has a potent suppressive effect on
histamine-induced wheal and flare.10,24,25 In patients
with AR subjected to nasal challenge, DL promoted
significant improvement in nasal flow and symptom score,
when compared with a placebo.26-28
Antiallergic and anti-inflammatory effects have been
described in vitro and in vivo.26,53
Results of double-blind, placebo-controlled trials,
indicate that LEV (5 mg/day) is effective for the treatment
of seasonal and persistent AR in adults and children from
6 to 12 years, improving all nasal symptoms including
obstruction.26,54-56
A meta-analysis demonstrated that LEV exhibits a
consistent effect on nasal obstruction within the first hours
after administration, maintaining this for 6 weeks.57
Additionally, LEV has been shown effective in adults for the
treatment of chronic idiopathic urticaria58,59 and for the
prevention of immediate and late symptoms resulting
from insect bites, particularly in patients with more intense
reactions.60
Levocetirizine does not interact significantly with any
of the muscarinic receptor subtypes and, does not therefore
manifest marked anticholinergic effects. This is a safe and
well-tolerated compound, with a minimum incidence of
adverse effects, which are comparable to placebo55,56,58
and other active treatments.61
When compared with placebo, LEV does not cause
sedation or any other deleterious effects on the cognition
and psychomotricity of healthy volunteers.62 In patients
with persistent AR and chronic idiopathic urticaria, LEV
significantly improved quality of life58,63 and reduced the
cost of prolonged treatment.63
Rupatadine
Rupatadine (RUP) is an H1 antihistamine that is capable
of interacting both with H1 receptors and with receptors
for platelet activation factor (PAF), therefore exerting an
H1 antihistamine and an anti-PAF effect. It has a rapid
onset of action and its effect is long-lasting, and it can be
a administrated once a day.64
A study using a cutaneous model demonstrated that
RUP has a potent peripheral H1 antihistamine effect,
suppressing histamine-induced wheal and flare, in a dose-
dependent manner.65 Antiallergic and anti-inflammatory
effects have been described in vitro.66
Randomized and controlled studies indicate that RUP
(10 mg/day) if effective for the treatment of AR from 12
years of age on, improving the score of nasal symptoms
(including obstruction) and non-nasal symptoms.67,68
This is a safe and well-tolerated compound, with a minimal
incidence of adverse effects, comparable with placebo68
and other active treatments.67
At the recommended dose (10 mg/day), when compared
to placebo, it does not produce any significant adverse
effect whatsoever on the cognitive or psychomotor function
of healthy volunteers.65 Similarly, the frequency of sedation
with RUP was similar to that observed with placebo.68
Finally, no clinically significant increases in QTc interval
were observed, even in the elderly and patients on
erythromycin and ketoconazole.64
It is worth mentioning that, although clinically significant
events have not been reported when RUP has been used
in association with other drugs that use the P450 cytochrome
route (erythromycin and ketoconazole), this type of
association should be avoided since RUP is metabolized
hepatically.64
Third-generation antihistamines
H1 antihistamines are highly effective at controlling
many allergic disorders, in particular rhinitis and urticaria.
Adverse effects associated with the use of first-generation
H1 antihistamines stimulated the search for compounds
that would be more effective and better tolerated  giving
rise to second-generation H1 antihistamines.
Although they offer better therapeutic index, other
adverse reactions came to be related to certain second-
generation H1 antihistamines, notably cardiotoxicity
(terfenadine and astemizole). Later refinements led to the
synthesis of other compounds, many of them in the form
of active metabolites. At this point the term third-
generation began to appear in the literature to describe
certain H1 antihistamines - a fact which became evident
during this review.
Apparently this term - third-generation - arose
spontaneously, with no clear definition or description of its
meaning, which, undoubtedly created much confusion,
both among general practitioners and among specialists.
Faced with this fact, scientists and clinicians uninvolved
with the pharmaceutical industry came together and
New antihistamines  Camelo-Nunes IC
178  Jornal de Pediatria - Vol. 82, No.5(Suppl), 2006
formed a Consensus Group on New Generation
Antihistamines (CONGA) which analyzed several critical
points, resulting in recommendations on the minimum
criteria that would have to be met for H1 antihistamines
could be reclassified and one could speak of a new class
or generation of H1 antihistamine.6 Some of the main
recommendations made by the CONGA are summed up
below.
Anti-inflammatory properties
To date it has not been possible to establish whether
the antiallergic/anti-inflammatory properties described in
many experimental models do in fact exist, and, if so, what
their true clinical significance is. These properties must be
demonstrated in vivo, in humans, at therapeutic doses
and under natural allergen exposure conditions.
For an H1 antihistamine to truly have antiallergic/anti-
inflammatory properties it must manifest, in humans,
superior efficacy to other therapies with the same properties
(for example, corticosteroids). Since the greatest
expression of allergic chronic inflammation is nasal
obstruction, these anti-inflammatory properties must
address this in a quantifiable manner. This must be
demonstrated, in particular, in persistent AR, in which
obstruction predominates over the other histamine-induced
symptoms.
Potency, efficacy and effectiveness
The therapeutic index of an H1 antihistamine, defined
as the risk-benefit relationship, is more important than its
potency (determined in preclinical trials) or its efficacy
(determined in clinical trials). In this sense, second-
generation H1 antihistamines have more favorable
therapeutic indices than the first generation ones, however
none of them merit the designation third-generation H1
antihistamine. It is probable that a true third-generation
H1 antihistamine will differ radically from existing
compounds.
Absence of cardiotoxicity
Adverse cardiac effects, with risk of life (QT prolongation
and torsades de pointes), were described with some
second-generation H1 antihistamine (terfenadine and
astemizole). These effects are the result of a direct block
to a specific class of potassium channels which control the
cardiac repolarization phase, and are not related to the
blockade of the H1 receptor. Therefore, cardiotoxicity is
not a class-specific effect.
Several  di f ferent pharmacokinet ic and
pharmacodynamic properties may precipitate an episode
of arrhythmia. Therefore, physicians using H1
antihistamines should be aware of these properties, in
order to avoid exposing their patients to potentially
dangerous effects.
Absence of cardiotoxic effects, a characteristic that
is already present in certain second-generation H1
antihistamines, must be maintained in the development
of new compounds. Preclinical and clinical trials
investigating their potential to cause such effects should
be performed before new molecules are released onto
the market.
Drug interactions
The possibility of drug interactions should never be
forgotten, primarily because H1 antihistamines are
commonly employed for prolonged periods. Based on this,
for an H1 antihistamine to be considered third-generation,
it must not: a) affect the function of any of the cytochrome
P 450 via enzymes; b) displace medications bonded to
plasma proteins; or c) affect active transport mechanisms
that are extremely important to the absorption and
excretion of drugs.
Lack of CNS effects
Three factors establish the criteria for determining
the nonsedative properties of an H1 antihistamine: a)
incidence of subjective somnolence; b) the objective
effect on cognitive and psychomotor functions; and c)
quantification of H1 receptor occupation using positronic
tomography. While the last two are particularly important,
all three factors must be met to a minimum acceptable
level before any new H1 antihistamine can be classed as
a nonsedative drug.
Final comments
Although H1 antihistamines are useful for the treatment
of allergic disorders, differences that are probably related
to their pharmacokinetic, pharmacodynamic, antiallergic
and anti-inflammatory properties mean that the many
different compounds in existence are not equally effective
for the control of symptoms of the skin, nose and lungs.
Furthermore, not all patients respond in the same manner
to all H1 antihistamines, and those who do not benefit from
one compound may respond satisfactorily to another.
Their antiallergic and anti-inflammatory effects,
together with the improved safety profile, make second-
generation antihistamines important elements for
continuous, long term regulation of both immediate and
late phase allergic reactions. However, it would be
premature to reclassify H1 antihistamines on the basis of
available evidence, since the diverse facets of these
medications have not yet been completely investigated
and their relative contribution to the global efficacy of
treatment for allergic disorders remains unknown.
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